Oragenics activates second site in Phase IIa trial for concussion drug ONP-002, enrolling patients rapidly.

Oragenics has activated a second clinical site at Alfred Hospital for its Phase IIa trial of ONP-002, a drug candidate for treating concussion and mild traumatic brain injury (mTBI). The trial, already enrolling patients at Mackay Base Hospital in Australia, aims to enroll 40 patients to evaluate ONP-002's effectiveness in reducing brain inflammation and injury symptoms. This drug could become the first FDA-approved pharmacological treatment for concussion, addressing a significant unmet medical need. Data from this trial is expected by the end of 2026, supporting a planned Phase IIb trial in the U.S.